Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration

Despite the success of anti-vascular endothelial growth factors (anti-VEGFs), currently, there is a need for highly effective compounds that can alleviate the burden of managing neovascular age-related macular degeneration (nAMD). To review the milestones in the molecular and clinical development of...

Celý popis

Podrobná bibliografia

Vydané v:	Ophthalmologica (Basel) Ročník 244; číslo 2; s. 93
Hlavní autori:	Tadayoni, Ramin, Sararols, Laura, Weissgerber, Georges, Verma, Rohini, Clemens, Andreas, Holz, Frank G
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Switzerland 01.05.2021
Predmet:	Neovascular age-related macular degeneration (AMD) Anti-VEGF Brolucizumab Single-chain antibody fragment
ISSN:	1423-0267, 1423-0267
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!